نتایج جستجو برای: braf mutation

تعداد نتایج: 295289  

2014
Marie-Luise Berres Karen Phaik Har Lim Tricia Peters Jeremy Price Hitoshi Takizawa Hélène Salmon Juliana Idoyaga Albert Ruzo Philip J. Lupo M. John Hicks Albert Shih Stephen J. Simko Harshal Abhyankar Rikhia Chakraborty Marylene Leboeuf Monique Beltrão Sérgio A. Lira Kenneth M. Heym Björn E. Clausen Venetia Bigley Matthew Collin Markus G. Manz Kenneth McClain Miriam Merad Carl E. Allen

Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive etiology, characterized by the accumulation of CD207(+) dendritic cells (DCs) in inflammatory lesions. Recurrent BRAF-V600E mutations have been reported in LCH. In this study, lesions from 100 patients were genotyped, and 64% carried the BRAF-V600E mutation within infiltrating CD207(+) DCs. BRAF-V600E expression in tissue DCs...

Journal: :Molecular cancer therapeutics 2015
Jeannelyn S Estrella Michael T Tetzlaff Roland L Bassett Keyur P Patel Michelle D Williams Jonathan L Curry Asif Rashid Stanley R Hamilton Russell R Broaddus

Although sequencing provides the gold standard for identifying colorectal carcinoma with BRAF V600E mutation, immunohistochemistry (IHC) with the recently developed mouse monoclonal antibody VE1 for BRAF V600E protein has shown promise as a more widely available and rapid method. However, we identified anecdotal discordance between VE1 IHC and sequencing results and therefore analyzed VE1 stain...

Journal: :Case reports in oncological medicine 2016
K Sahadudheen Md Rafiqul Islam M Iddawela

Introduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival, and response rates in patients with metastatic melanoma with BRAF V600K mutation. However, there were no cases of complete remission reported in patients with V600K mutation before. Case Presentation. A 53-year-old man with metastatic melanoma and dialysis dependent en...

2013
L Lodé P Moreau A Ménard C Godon C Touzeau M Amiot S Le Gouill M C Béné C Pellat-Deceunynck

After whole genome sequencing of samples from 38 patients with multiple myeloma (MM) had identified one patient with an activating mutation of BRAF (G469A), BRAF mutations have been intensively screened in MM patients. Among 161 samples, 3 K601N and 4 V600E (the most common in melanoma) mutations were found in 4% of the patients. This low incidence is still consistent with a recent study involv...

2016
Jian Sun Jing Zhang Junliang Lu Jie Gao Xinyu Ren Lianghong Teng Huanli Duan Yansong Lin Xiaoyi Li Bo Zhang Zhiyong Liang

BACKGROUND The BRAF V600E and telomerase reverse transcriptase (TERT) promoter mutations have been reported in papillary thyroid carcinoma (PTC). The aim of this retrospective cross-sectional study was to add further information regarding the prevalence of the BRAF V600E and TERT promoter mutations in Chinese PTC and their clinicopathological associations. METHODS We detected the BRAF V600E m...

2015
Hsin-Chieh Tang Yu-Chian Chen

BRAF inhibitors have changed the standard therapeutic protocol for advanced or metastatic melanoma which harbored notorious BRAF(V600E) single mutation. However, drug resistance to BRAF inhibitors happens just like other cancer treatment. In this study, we constructed the ideal BRAF(V600E)-modeled structure through homology modeling and introduced the method of structure-based docking or virtua...

Journal: :Molecular cancer therapeutics 2009
Narendra Wajapeyee Varun Kapoor Meera Mahalingam Michael R Green

We recently identified the secreted protein IGFBP7 as a factor required for an activated BRAF oncogene to induce senescence or apoptosis in primary human cells. In human melanomas containing an activating BRAF mutation (BRAF-positive melanomas), IGFBP7 is epigenetically silenced, which seems to be a critical step in melanoma genesis. Restoration of IGFBP7 function by the addition of recombinant...

2015
Zhiyu Tang Xi Yuan Rong Du Shing-Hu Cheung Guoliang Zhang Jing Wei Yuan Zhao Yingcai Feng Hao Peng Yi Zhang Yunguang Du Xiaoxia Hu Wenfeng Gong Yong Rui Hao Shengjian Li Shaohui Wang Jiafu Ji Lianhai Zhang Shuangxi Li David Sutton Min Wei Changyou Zhou Lusong Luo

Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF metastatic melanoma, their clinical efficacy inBRAF colorectal cancer is far less impressive. Prior studies suggested that fe...

2013
Seung-Hyun Lee Byung-Kwon Ahn Sung-Uhn Baek Hee-Kyung Chang

AIMS Recently, BRAF mutation testing has been introduced as a marker in differentiating Lynch syndrome from sporadic colorectal cancers or in predicting colorectal cancers with worse prognosis. Individuals with hereditary predisposition to cancer development are at an increased risk of developing multiple primary cancers. The purpose of this study is to identify mutation in the BRAF gene in mul...

2017
Martine A Frouws Marlies S Reimers Marloes Swets Esther Bastiaannet Bianca Prinse Ronald van Eijk Valery E P P Lemmens Myrthe P P van Herk-Sukel Tom van Wezel Peter J K Kuppen Hans Morreau Cornelis J H van de Velde Gerrit-Jan Liefers

BACKGROUND Use of aspirin after diagnosis of colon cancer has been associated with improved survival. Identification of cancer subtypes that respond to aspirin treatment may help develop personalized treatment regimens. The aim of this study was to investigate the influence of BRAF and KRAS mutation status on the association between aspirin use and overall survival after colon cancer diagnosis....

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید